Literature DB >> 8717408

Toward selective elicitation of TH1-controlled vaccination responses: vaccine applications of bacterial surface layer proteins.

B Jahn-Schmid1, P Messner, F M Unger, U B Sleytr, O Scheiner, D Kraft.   

Abstract

Bacterial surface layer proteins have been utilized as combined vaccine carrier/adjuvants and offer a number of advantages in these applications. The crystalline protein arrays contain functional groups in precisely defined orientations for coupling of haptens. Conventional applications of S-layer vaccines do not cause observable trauma or side effects. Depending on the nature of the S-layer preparations, antigenic conjugates will induce immune responses of a predominantly cellular or predominantly humoral nature. Immune responses to S-layer-hapten conjugates are also observed following oral/nasal application. In the present contribution, the status of investigations with S-layer conjugates in three main immunological projects is reviewed. In a project aimed at immunotherapy of cancer, conjugates of S-layer with small, tumor-associated oligosaccharides have been found to elicit hapten-specific DTH responses. An enlarged program of chemical synthesis has now been initiated to prepare a complete set of mucin-derived, tumor-associated oligosaccharides and their chemically modified analogues for elicitation of cell-mediated immune responses to certain tumors in humans. In another application, oligosaccharides derived from capsules of Streptococcus pneumoniae type 8 have been linked to S-layer proteins and have been found to elicit protective antibody responses in animals. Most recently, allergen S-layer conjugates have been prepared with the intention to suppress the TH2-directed, IgE-mediated allergic responses to Bet nu 1, the major allergen of birch pollen. In the former two applications, the S-layer vaccine technology appears to offer the versatility needed to direct vaccination responses toward predominant control by TH1 or TH2 lymphocytes to meet the different therapeutic or prophylactic requirements in each case. In the third application, work has progressed to a preliminary stage only.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717408     DOI: 10.1016/0168-1656(95)00124-7

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  8 in total

Review 1.  S-Layer proteins.

Authors:  M Sára; U B Sleytr
Journal:  J Bacteriol       Date:  2000-02       Impact factor: 3.490

2.  A pyrophosphate bridge links the pyruvate-containing secondary cell wall polymer of Paenibacillus alvei CCM 2051 to muramic acid.

Authors:  C Schäffer; N Müller; P K Mandal; R Christian; S Zayni; P Messner
Journal:  Glycoconj J       Date:  2000-10       Impact factor: 2.916

3.  Immunization with a ZmpB-based protein vaccine could protect against pneumococcal diseases in mice.

Authors:  Yi Gong; Wenchun Xu; Yali Cui; Xuemei Zhang; Run Yao; Dairong Li; Hong Wang; Yujuan He; Ju Cao; Yibing Yin
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

4.  Heterologous prime-boost immunization with live SPY1 and DnaJ protein of Streptococcus pneumoniae induces strong Th1 and Th17 cellular immune responses in mice.

Authors:  Yulan Qiu; Xuemei Zhang; Hong Wang; Xinyuan Zhang; Yunjun Mo; Xiaoyu Sun; Jichao Wang; Yibing Yin; Wenchun Xu
Journal:  J Microbiol       Date:  2017-09-28       Impact factor: 3.422

5.  S-layers: principles and applications.

Authors:  Uwe B Sleytr; Bernhard Schuster; Eva-Maria Egelseer; Dietmar Pum
Journal:  FEMS Microbiol Rev       Date:  2014-02-24       Impact factor: 16.408

Review 6.  Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: Set the bugs to work?

Authors:  Fatemeh Farjadian; Mohsen Moghoofei; Soroush Mirkiani; Amir Ghasemi; Navid Rabiee; Shima Hadifar; Ali Beyzavi; Mahdi Karimi; Michael R Hamblin
Journal:  Biotechnol Adv       Date:  2018-02-28       Impact factor: 14.227

Review 7.  Decorating and loading ghosts with allergens for allergen immunotherapy.

Authors:  Songwe Fanuel; Saeideh Tabesh; Huda Fatima Rajani; Sahel Heidari; Esmaeil Sadroddiny; Gholam Ali Kardar
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

8.  Mucosal immunization with recombinant fusion protein DnaJ-ΔA146Ply enhances cross-protective immunity against Streptococcus pneumoniae infection in mice via interleukin 17A.

Authors:  Yusi Liu; Hong Wang; Shuai Zhang; Lingbin Zeng; Xiuyu Xu; Kaifeng Wu; Wei Wang; Nanlin Yin; Zhixin Song; Xuemei Zhang; Yibing Yin
Journal:  Infect Immun       Date:  2014-02-03       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.